CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (Nasdaq:IVGN) today announced results for its third quarter ended September 30, 2006. Revenues for the third quarter were $311 million, an increase of 7% over the $290 million reported for the third quarter of 2005. Foreign currency translation had a positive 1 percentage point impact on sales growth rate. Net loss for the third quarter was $130 million versus a net income of $24 million for the same quarter in 2005. The third quarter net loss was due to a non-cash charge of $150 million associated with a goodwill impairment within the Cell Culture Systems segment. GAAP earnings per share for the third quarter of 2006 were a loss of $2.53 per share, as compared to a gain of $0.42 per share reported in the third quarter of 2005. Earnings per share in third quarter 2006 includes the impact from goodwill impairment of $2.85 per share, and stock option expense of $.15 per share.
